PSMD9 can serve as a diagnostic and prognostic marker for personalizing GBM therapy; panobinostat inhibits GBM progression by targeting PSMD9 and provides a valuable potential treatment for GBM. The gene discussed is PSMD9; the disease is glioblastoma.